Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGO...
| Metric Name | Value | Trend | |
|---|---|---|---|
| Dividend Yield | 0.0% | ||
| P/E Ratio | -9.5x | ||
| Revenue | 705.1 M | ||
| Net Income to Company | -453.9 M |
| IONS | Peers | Sector | |
|---|---|---|---|
Market Cap | 4.534 B | 340.7 M | 62.454 M |
Price % of 52 Week High | 51.6% | 34.7% | 61.1% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | -11.3% | -32.9% | -0.7% |
1 Year Price Total Return | -33.4% | -48.2% | -13.2% |
Beta (5 Year) | 0.29 | 1.09 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 587 | 788 | 705 | 325 | 227 |
| Operating Income | (410) | (334) | (475) | 14 | (111) |
| Net Profit | (270) | (366) | (454) | (9.26) | (104) |
| Diluted EPS | -1.90 | -2.56 | -3.04 | -0.064 | -0.66 |
| EBITDA | (393) | (321) | (463) | 17 | (108) |
| Balance Sheet | |||||
| Cash & ST Invest. | 1,997 | 2,338 | 2,303 | 2,338 | 2,303 |
| Current Assets | 2,203 | 2,642 | 2,620 | 2,642 | 2,620 |
| Total Assets | 2,534 | 2,990 | 3,004 | 2,990 | 3,004 |
| Current Liabilities | 312 | 448 | 309 | 448 | 309 |
| Total Liabilities | 1,961 | 2,603 | 2,415 | 2,603 | 2,415 |
| Total Equity | 573 | 387 | 588 | 387 | 588 |
| Total Debt | 1,369 | 1,967 | 1,959 | 1,967 | 1,959 |
| Cash Flow Statement | |||||
| Cash Flow Operations | (274) | (308) | (501) | 33 | (116) |
| Cash From Investing | (263) | (214) | (134) | (27) | 68 |
| Cash From Financing | (55) | 644 | 478 | 41 | (44) |
| Free Cash Flow | (290) | (331) | (546) | 34 | (142) |